insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

SOUTH SAN FRANCISCO, Calif., January 12, 2026--insitro, the AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro’s TherML™ ...

Voice Modality: The Next Frontier In AI And Workflow

The productivity upside is straightforward. Research, like the Stanford report linked above, has repeatedly shown that ...
GEN - Genetic Engineering and Biotechnology News

1910 Unlocks Macrocyclic Peptide Drugs Using PEGASUS AI Model

PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill ...
The Victoria Advocate

Target ALS and Modality.AI Collaborate in Multimodal Study of ALS

Direct-to-participant study to reach 150 people living with ALS, with 2 participants already enrolled. NEW YORK, Sept. 26, 2024 /PRNewswire/ -- In a first-of-a-kind collaboration, Target ALS, a ...
WDTN

ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

VICTORIA, BC / ACCESSWIRE / November 22, 2023 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has announced that its subsidiary, BioStrand®, ...